10 Jahre Erfahrung mit der Ruthenium-106/Rhodium-106-Behandlung des malignen Melanoms der Aderhaut - Bericht über 264 bestrahlte Tumoren

Guthoff, R.; Domarus, D. von; Steinhorst, U.; Hallermann, D.

doi:10.1055/s-2008-1050719

Cited by 22 publications

(8 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some claim that 75"/0 of patients that have ruthenium plaque radiotherapy for posterior uveal melanoma retain useful vision (Guthoff et al 1986;Tjho-Heslinga et al 1993), or that pre-treatment visual acuity is preserved in 72% of patients (Muller et al 1986). However, to compare the visual outcome in different groups of patients receiving plaque radiotherapy is exceedingly difficult.…”

Section: Discussionmentioning

confidence: 99%

“…Ruthenium plaque radiotherapy for posterior uveal melanoma was conceptualized in the 1960s and subsequently popularized by Lommatzsch (Lommatzsch & Vollmar 1966;Lommatzsch 1986). Since then, brachytherapy using ruthenium 106 has been adopted by a large number of ocular oncology centres (Guthoff et al 1986;Miiller et al 1986;Shields et al 1989;Grange et al 1990;Bacin et al 1991;Summanen et al 1993;Tjho-Heslinga et al 1993;Kleineidam et al 1993). In Sweden, ruthenium plaque radiotherapy was introduced in 1979 and the facilities have remained confined to one centre.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma The Swedish experience

Seregard

Trampe

Lax

et al. 1997

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT. The Swedish experience of ruthenium 106 plaque radiotherapy for posterior uveal melanoma includes 266 patients treated between 1979 and 1995. The median dose delivered at the tumour apex was 100 Gy and the median follow-up after radiotherapy was 3.6 years (range = 0.5 to 12.5 years) with no patient being lost to follow-up. Visual acuity deteriorated moderately following treatment but appeared to stabilize after 5 to 6 years. Treatment failure defined as enucleation following plaque treatment occurred in 46 of the 266 (17%) studied patients. The cumulative 5-year probability of retaining the eye after radiotherapy was 82% and by univariate analysis tumour height, tumour diameter and tumour stage each predicted subsequent treatment failure, whereas in multivariate analysis no single covariate retained a predictive value. Forty-five of the 266 patients died of any cause during follow-up; 27 of these deaths were melanoma-related. The cumulative 5-year survival proportion (based on melanoma-related deaths only) was 86%. Death in metastatic disease appeared to be more common among patients that failed ruthenium plaque radiotherapy, however these patients also tended to have large tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma The Swedish experience

Seregard

Trampe

Lax

et al. 1997

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…Die Wirksamkeit der Schalen bei kleinen and mittelgroBen Tumoren and einer maximalen Tumorhohe von 5 mm wurde bislang in zahlreichen Studien belegt [1,7,12,13,18]. So liegt z.…”

Section: Tumorkontrollrate Uberlebenunclassified

“…Diese hangt einerseits von der GrWe der zu behandelnden Tumoren, von der Lokalisation and moglicherweise, wie bereits an anderer Stelle erwahnt, auch von der Dosisrate der Rutheniumschalen ab. Wenn man Lesevisus mit 0,5 and mehr definiert, erreichten bei Hallermann 32% [8], bei Guthoff 36% [7] Lesevermogen, in unserer Studie waren es 34% (64% hatten Lesevermogen vor Therapie). Lommatzsch weist in seiner Publikation mit der bislang langsten Verlaufsbeobachtungsdauer [13] auf eine uber viele Jahre langsame Sehverschlechterung hin.…”

Section: Sehvermogenunclassified

Über den Stellenwert der Ruthenium-106- Brachytherapie bei der Therapie von Aderhautmelanomen

Langmann¹,

Mosböck²,

Stücklschwaiger³

et al. 2002

Spektrum Augeheilkd

View full text Add to dashboard Cite

Graz seit ihrer Einfiihrung im Jahr 1985 mit Ruthenium 106 behandelten Aderhautmelanome wurden in Hinblick auf klinischen Verlauf, Komplikationen and Sehscharfe untersucht. Patienten and Methode: In Form einer retrospektiven Studie wurden 47 Patienten, die zwischen 1985 and 2000 mit Ruthenium 106 behandelt wurden (medianer Nachbeobachtungszeitraum 22 Monate [8-152 Monate]), mittels Kaplan Meiers statistischer Evaluierung untersucht.Ergebnisse: Die lokale Tumorkontrollrate betrug 85%, die 5-Jahres-Wahrscheinlichkeit, eine Enukleation zu vermeiden, 72%. Die haufigsten Nebenwirkungen waren radiogene Optikuslasion (29%), Makulopathie (37%) and Strahlenretinopathie (32%). Bei Abschluss der Studie erreichten 34% der Patienten einen Visus von zumindest 0,5, 34% der Patienten hatten ein Sehvermogen von unter 0,1.Zusammenfassung: Die Rutheniumtherapie ist unsere Methode der Wahl bei kleinen and mittelgrolien Tumoren der mittleren and aulleren Peripherie and des Ziliarkorpers mit einer maximalen Tumorhohe von 6 mm. Erganzend zu den von Lommatzsch ursprunglich angegebenen Indikationen konnen Ziliarkorpermelanome mit einer Basis von mehr als 3 Stunden alternativ mit Ruthenium-106-Applikatoren behandelt werden (durch Shiften der Applikatoren). Schlasselworter: Ruthenium 106 Brachytherapie, Aderhautmelanome, Sehscharfe.About the value of Ruthenium 106 brachytherapy in the treatment of uveal melanomas Summary. Background: to investigate the clinical course, sequelae and visual function of uveal melanomas treated with Ruthenium 106 brachytherapy.Patients and method: 47 patients who underwent Ruthenium 106 brachytherapy between 1985 and 2000 were evaluated using Kaplan Meier statistical method. Mean follow up interval was 22 months (range 8-152 months).Results: Local tumor control rate was 85%, 5 years possibility to avoid enucleation was 72%. The most important * Teile dieser Publikation wurden wahrend der Jahrestagung der Osterreichischen Ophthalmologischen Gesellschaft in Millstatt als Posterdemonstration vorgestellt. sequelae were radiation optic neuropathy (29%), maculopathy (37%) and radiation retinopathy (32%). After terminating the study 34% of the patients achieved a visual acuity of 20/40 and more, another 34% had a visual function of 20/200 and lower.Conclusion: Ruthenium 106 brachytherapy is our method of choice in small to medium sized uveal melanomas and a maximum tumor prominence of 6 mm. tumors have to be located in the midperiphery and outer periphery of the fundus including the ciliary body. In addition to the indications introduced by Lommatzsch we treated ciliary body melanomas with a tumor base more than 3 clock hours (by shifting the plaque) as an alternative therapy to enucleation.

show abstract

“…For over two decades, ruthenium-106 eye applicators [1] have been used for the irradia tion treatment of malignant melanomas of the eye [2][3][4][5]. The low range of the electrons (maximum energy 3.5 MeV) in tissue allows for high tumor doses while at the same time sparing such delicate eye structures as the crystalline lens, the chamber angle and the optic nerve.…”

Section: Introductionmentioning

confidence: 99%

Results and Implications of High-Resolution Surface Dosimetry of Ruthenium-106 Eye Applicators

Menapace

Binder

Chiari³

1992

Ophthalmologica

View full text Add to dashboard Cite

The dosimetry of ¹⁰⁶Ru/¹⁰⁶Rh Β-emitting eye applicators is still inadequate. Manufacturer’s specifications of absolute dose rates are loaded with a ± 30% error, and the relative distribution of activity on the surface is measured on a few points only, using a 3-mm plastic scintillation probe. While reducing the absolute error of dose rate measurements to ± 15% by a method published earlier, we now present a phantom using small thermoluminescent dosimetry crystals for refined assessment of its distribution over the surface. Evaluation of two applicators revealed a 50% increase in activity in the midperiphery in one and a steep falloff of activity 1 mm within the margin of both specimens. The method and findings are demonstrated in detail and compared to those reported by other authors.

show abstract

10 Jahre Erfahrung mit der Ruthenium-106/Rhodium-106-Behandlung des malignen Melanoms der Aderhaut - Bericht über 264 bestrahlte Tumoren

Cited by 22 publications

References 1 publication

Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma The Swedish experience

Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma The Swedish experience

Über den Stellenwert der Ruthenium-106- Brachytherapie bei der Therapie von Aderhautmelanomen

Results and Implications of High-Resolution Surface Dosimetry of Ruthenium-106 Eye Applicators

Contact Info

Product

Resources

About